Northwest Biotherapeutics – Glioblastoma Multiforme

Access Program Information

The study is an open-label expanded access study for patients for whom vaccine was
manufactured during the Northwest Biotherapeutics’ 020221 DCVax-L for GBM screening process,
but who subsequently failed to meet specific enrollment criteria. Patients will receive
therapy per investigator discretion (standard of care) as well as active vaccine per the
020221 protocol administration schedule. It is estimated that approximately 99 patients will
enroll in this study.

Rare Disease: